Signal mining and analysis of adverse drug events of baloxavir marboxil based on American FAERS

LIN Jing; YANG Wenbao; LYU Lingtong

doi:10.6039/j.issn.1001-0408.2023.07.19

您当前的位置：

首页 >

文章列表页 >

Signal mining and analysis of adverse drug events of baloxavir marboxil based on American FAERS

更新时间：2024-02-19

- Signal mining and analysis of adverse drug events of baloxavir marboxil based on American FAERS
- ZHONGGUO YAOFANG Vol. 34, Issue 7, Pages: 868-871(2023)
- 作者机构：
  
  1.济南市市中区人民医院药学部，济南　250002
  2.济南市市中区人民医院西药房，济南　250002
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.07.19
  CLC： R978.7;R969.3
- Published：15 April 2023，
  
  Received：20 September 2022，
  
  Revised：24 March 2023，
扫描看全文
林静,杨文宝,吕灵通.基于美国FAERS的玛巴洛沙韦不良事件信号挖掘与分析 ^Δ[J].中国药房,2023,34(07):868-871.

LIN Jing,YANG Wenbao,LYU Lingtong.Signal mining and analysis of adverse drug events of baloxavir marboxil based on American FAERS[J].ZHONGGUO YAOFANG,2023,34(07):868-871.
林静,杨文宝,吕灵通.基于美国FAERS的玛巴洛沙韦不良事件信号挖掘与分析 ^Δ[J].中国药房,2023,34(07):868-871. DOI： 10.6039/j.issn.1001-0408.2023.07.19.

LIN Jing,YANG Wenbao,LYU Lingtong.Signal mining and analysis of adverse drug events of baloxavir marboxil based on American FAERS[J].ZHONGGUO YAOFANG,2023,34(07):868-871. DOI： 10.6039/j.issn.1001-0408.2023.07.19.

摘要

目的

挖掘玛巴洛沙韦相关药品不良事件（ADE）信号，为临床安全用药提供参考。

方法

利用比例报告比（PRR）法对美国FDA不良事件报告系统（FAERS）中2018年1月1日－2022年5月31日上报的有关玛巴洛沙韦的ADE信号进行挖掘。将报告数≥3、PRR≥2且

≥4的ADE定义为阳性信号，并采用PRR法对ADE信号进行分析。

结果

共收集到玛巴洛沙韦为主要怀疑药物的ADE报告1 424例，涉及ADE信号460个。女性和18岁以下患者的报告数较多；上报数最多的国家是美国；报告中药品的主要适应证为流感。通过PRR法计算及筛选排除后共获得37个ADE阳性信号，其中上报数位于前3位的ADE信号分别为腹泻、呕吐和速发型过敏反应，PRR值位于前3位的ADE信号分别为热性谵妄、缺血性结肠炎和出血性膀胱炎。与玛巴洛沙韦说明书对比，有18个ADE信号尚未被说明书收录，如肝功能异常、血尿、出血性膀胱炎等；涉及5个新的SOC，包括肾脏及泌尿系统疾病、肝胆系统疾病、各类检查、各类神经系统疾病和各种肌肉骨骼及结缔组织疾病。

结论

临床应用玛巴洛沙韦时，除了关注说明书中记载的不良反应外，还应关注肝功能异常、血尿、出血性膀胱炎等，以保障患者用药安全。

Abstract

OBJECTIVE

To mine adverse drug event （ADE） signals related to baloxavir marboxil， and to provide reference for clinically safe drug use.

METHODS

The ADE signals related to baloxavir marboxil from January 1， 2018 to May 31， 2022 in the US FDA adverse event reporting system （FAERS） were mined using the proportional reporting odds ratio （PRR） method. ADE with report number≥3， PRR≥2 and

≥4 was defined as a positive signal， and PRR method was used to analyze the ADE signal.

RESULTS

A total of 1 424 ADE reports with baloxavir marboxil as the main suspected drug were collected， involving 460 ADE signals. The femininity and patient under 18 years old were reported more， the country with the highest number of reports was the United States， and the main indication of drug reported was influenza. A total of 37 ADE positive signals were obtained after PRR calculation and screening exclusion， the first three ADE signals in the list of the reported number were diarrhea， vomiting and immediate hypersensitivity， and the first three ADE signals in the list of PRR value were febrile delirium， ischaemic colitis and hemorrhagic cystitis. Compared with the instructions of baloxavir marboxil， 18 ADE signals had not yet been included， such as abnormal liver function， hematuria， hemorrhagic cystitis， etc. Five new SOCs were involved， such as kidney and urinary system diseases， hepatobiliary system diseases， investigations， nervous system disorders and musculoskeletal and connective tissue disorders.

CONCLUSIONS

When clinical application of baloxavir marboxil， in addition to the adverse drug reactions mentioned in the drug instructions， attention should be paid to abnormal liver function， hematuria， hemorrhagic cystitis， etc， so as to guarantee the safety of drug use.

关键词

玛巴洛沙韦药品不良事件药物警戒比例报告比法安全用药

Keywords

adverse drug eventpharmacovigilanceproportional reporting ratiodrug safe use

references

郭寿清，廖月姣，乔自林，等. 宿主miRNA参与甲型流感病毒复制调控研究进展[J]. 病毒学报，2022，38（2）：494-504.

ŚWIERCZYŃSKA M，MIROWSKA-GUZEL D M，PINDELSKA E. Antiviral drugs in influenza[J]. Int J Environ Res Public Health，2022，19（5）：3018.

O'HANLON R，SHAW M L. Baloxavir marboxil：the new influenza drug on the market[J]. Curr Opin Virol，2019，35：14-18.

KASS-HOUT T A，XU Z H，MOHEBBI M，et al. OpenFDA：an innovative platform providing access to a wealth of FDA’s publicly available data[J]. J Am Med Inform Assoc，2016，23（3）：596-600.

EVANS S J W，WALLER P C，DAVIS S. Use of proportional reporting ratios （PRRs） for signal generation from spontaneous adverse drug reaction reports[J]. Pharma- coepidemiol Drug Saf，2001，10（6）：483-486.

SLATTERY J，ALVAREZ Y，HIDALGO A. Choosing thresholds for statistical signal detection with the proportional reporting ratio[J]. Drug Saf，2013，36（8）：687-692.

ROTROSEN E T，NEUZIL K M. Influenza：a global per- spective[J]. Pediatr Clin North Am，2017，64（4）：911-936.

Uyeki T M，Hui D S，Zambon M，et al. Influenza[J]. Lancet，2022，400（10353）：693-706.

KAMIDANI S，GARG S，ROLFES M A，et al. Epidemio- logy，clinical characteristics，and outcomes of influenza associated hospitalizations in US children over 9 seasons following the 2009 H1N1 pandemic[J]. Clin Infect Dis，2022，75（11）：1930-1939.

NAKAZAWA M，HARA K，KOMEDA T，et al. Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice：a postmarketing surveillance of more than 3 000 patients[J]. J Infect Chemother，2020，26（7）：729-735.

BAKER J，BLOCK S L，MATHARU B，et al. Baloxavir marboxil single-dose treatment in influenza-infected children：a randomized，double-blind，active controlled phase 3 safety and efficacy trial （miniSTONE-2）[J]. Pediatr Infect Dis J，2020，39（8）：700-705.

HARRISON C. Coronavirus puts drug repurposing on the fast track[J]. Nat Biotechnol，2020，38（4）：379-381.

YANG Y，TANG H. Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia[J]. Cell Mol Immunol，2016，13（4）：432-442.

BITZAN M，ZIEG J. Influenza-associated thrombotic microangiopathies[J]. Pediatr Nephrol，2018，33（11）：2009-2025.

KANAI N，HASHIMOTO T，FUKUDA M，et al. Acute ischemic colitis with hematochezia related to baloxavir marboxil treatment for influenza A[J]. J Infect Chemother，2019，25（12）：1040-1042.

HARA A，HARA K，KOMEDA T，et al. Comparison of the incidence of bleeding between baloxavir marboxil and other anti-influenza drugs among outpatients with influenza virus infection：a retrospective cohort study using an employment-based health insurance claims database in Japan[J]. Pharmacoepidemiol Drug Saf，2022，31（6）：623-631.

KOSHIMICHI H，ISHIBASHI T，KAWAGUCHI N，et al. Safety，tolerability，and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults：phase Ⅰ study findings[J]. Clin Drug Investig，2018，38（12）：1189-1196.

CHEN Y Y. Abnormal liver chemistry in patients with influenza A H1N1[J]. Liver Int，2011，31（6）：902.

吴斌，吴逢波，何治尧，等. 基于美国FDA不良事件报告系统的硫唑嘌呤相关死亡事件数据挖掘研究[J]. 中国药房，2019，30（21）：2993-2997.

毕玉侠，吴春福，杨静玉. 美国食品与药物管理局药品不良反应信号的定量评价方法概述及启示[J]. 中国药房，2010，21（18）：1640-1642.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Establishment of the method for the content determination of patulin in Citri Grandis Exocarpium

我院1 419 例药品不良反应报告分析

儿童监护人安全用药知识认知度的调查分析

胸腺激素类药致少见不良反应分析

1 611例药品不良反应报告分析

Related Author

WANG Yanhui

LI Jianming

GU Lihong

XIE Simin

CHEN Junfei

HOU Huichan

韩峰康云婷

陈敏玲吴娟张顺国

Related Institution

Guangzhou Institute for Drug Control/Key Laboratory for Quality Evaluation of Chinese Patent Medicine，National Medical Products Administration

Guangzhou Xiangxue Pharmaceutical Co.， Ltd.

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰